Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
2 studies found for:    19536906 [PUBMED-IDS]
Show Display Options
Rank Status Study
1 Completed
Has Results
Dasatinib (BMS-354835) Versus Imatinib Mesylate in Subjects With Chronic Myeloid Leukemia
Conditions: Chronic Myeloid Leukemia;   Philadelphia-Positive Myeloid Leukemia
Interventions: Drug: Dasatinib;   Drug: Imatinib
2 Unknown  BMS-354825 or Imatinib Mesylate in Treating Patients With Chronic Phase Chronic Myelogenous Leukemia That Did Not Respond to Previous Imatinib Mesylate
Condition: Leukemia
Interventions: Drug: dasatinib;   Drug: imatinib mesylate

Indicates status has not been verified in more than two years